Amy Manley

1.4k total citations
28 papers, 1.1k citations indexed

About

Amy Manley is a scholar working on Pharmacology, Molecular Medicine and Infectious Diseases. According to data from OpenAlex, Amy Manley has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 12 papers in Molecular Medicine and 10 papers in Infectious Diseases. Recurrent topics in Amy Manley's work include Antibiotic Resistance in Bacteria (12 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Antibiotic Use and Resistance (8 papers). Amy Manley is often cited by papers focused on Antibiotic Resistance in Bacteria (12 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Antibiotic Use and Resistance (8 papers). Amy Manley collaborates with scholars based in United States, Romania and Poland. Amy Manley's co-authors include Evan Tzanis, Lynne Garrity-Ryan, Stephen Villano, Judith N. Steenbergen, Paul B. Eckburg, Anita Das, Evan Loh, Surya Chitra, Paul C. McGovern and Nicholas DeMartinis and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Clinical Infectious Diseases.

In The Last Decade

Amy Manley

26 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Manley United States	15	459	341	327	313	172	28	1.1k
Evan Tzanis United States	23	418 0.9×	380 1.1×	392 1.2×	350 1.1×	187 1.1×	68	1.6k
Phil Wiffen United Kingdom	8	289 0.6×	114 0.3×	176 0.5×	200 0.6×	176 1.0×	39	1.4k
Mark H. Gotfried United States	34	1.2k 2.6×	988 2.9×	1.3k 4.0×	441 1.4×	202 1.2×	87	3.4k
P Léophonte France	20	198 0.4×	147 0.4×	877 2.7×	129 0.4×	92 0.5×	97	1.4k
Nicholas M. Moore United States	18	158 0.3×	397 1.2×	264 0.8×	286 0.9×	151 0.9×	54	1.2k
Koji Narui Japan	23	40 0.1×	134 0.4×	131 0.4×	235 0.8×	63 0.4×	80	1.6k
Eric Shore United States	15	259 0.6×	208 0.6×	336 1.0×	165 0.5×	62 0.4×	23	930
D. J. Flournoy United States	18	107 0.2×	138 0.4×	273 0.8×	206 0.7×	71 0.4×	97	866
Michael Hesney United States	13	291 0.6×	109 0.3×	234 0.7×	380 1.2×	59 0.3×	25	896
Luigi Celani Italy	11	200 0.4×	352 1.0×	194 0.6×	271 0.9×	125 0.7×	25	802

Countries citing papers authored by Amy Manley

Since Specialization

Citations

This map shows the geographic impact of Amy Manley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Manley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Manley more than expected).

Fields of papers citing papers by Amy Manley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Manley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Manley. The network helps show where Amy Manley may publish in the future.

Co-authorship network of co-authors of Amy Manley

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Manley. A scholar is included among the top collaborators of Amy Manley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Manley. Amy Manley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

File, Thomas M., Keith S. Kaye, Kushagra Gupta, et al.. (2025). Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial. EClinicalMedicine. 90. 103656–103656.

Torres, Antoni, Lynne Garrity-Ryan, Judith N. Steenbergen, et al.. (2021). Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. International Journal of Infectious Diseases. 104. 501–509. 11 indexed citations

Sakoulas, George, Paul B. Eckburg, Maria Amodio-Groton, et al.. (2021). Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies. Open Forum Infectious Diseases. 8(6). ofab136–ofab136. 8 indexed citations

Hunt, Thomas L., Evan Tzanis, Stephen A. Bai, et al.. (2020). The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study. European Journal of Drug Metabolism and Pharmacokinetics. 46(1). 85–92. 16 indexed citations

Overcash, J. Scott, Evan Tzanis, Amy Manley, et al.. (2020). 1687. Omadacycline in Female Adults With Acute Pyelonephritis: Results from a Randomized, Double-Blind, Adaptive Phase 2 Study. Open Forum Infectious Diseases. 7(Supplement_1). S827–S827. 4 indexed citations

O’Riordan, William, Lynne Garrity-Ryan, Anita Das, et al.. (2019). Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. The Lancet Infectious Diseases. 19(10). 1080–1090. 73 indexed citations

Ramírez, Julio A., Evan Tzanis, Robert Noble, et al.. (2019). Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice. Clinical Infectious Diseases. 69(Supplement_1). S33–S39. 10 indexed citations

Popescu, Monica, Ismail Mitha, William Nseir, et al.. (2019). Omadacycline for Community-Acquired Bacterial Pneumonia. New England Journal of Medicine. 380(6). 517–527. 171 indexed citations

Overcash, J. Scott, Lynne Garrity-Ryan, Judith N. Steenbergen, et al.. (2019). Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study. Antimicrobial Agents and Chemotherapy. 63(5). 29 indexed citations

10.

Sakoulas, George, Paul B. Eckburg, Amy Manley, et al.. (2019). 110. Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies. Open Forum Infectious Diseases. 6(Supplement_2). S86–S87. 1 indexed citations

11.

Abrahamian, Fredrick M., George Sakoulas, Evan Tzanis, et al.. (2018). 1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials. Open Forum Infectious Diseases. 5(suppl_1). S412–S412. 3 indexed citations

12.

Darpö, Börje, Evan Tzanis, Lynne Garrity-Ryan, et al.. (2017). Cardiac Safety of Omadacycline in the IV/oral Phase 3 Acute Bacterial Skin and Skin Structure Infection (ABSSSI) and in the IV/oral Phase 3 Community-acquired Bacterial Pneumonia (CABP) Studies. Open Forum Infectious Diseases. 4(suppl_1). S544–S545. 4 indexed citations

13.

Popescu, Monica, Ismail Mitha, Andrzej Madej, et al.. (2017). A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study). Open Forum Infectious Diseases. 4(suppl_1). S543–S544. 11 indexed citations

14.

Tzanis, Evan, Amy Manley, Stephen Villano, et al.. (2016). Effect of Food on the Bioavailability of Omadacycline in Healthy Participants. The Journal of Clinical Pharmacology. 57(3). 321–327. 37 indexed citations

15.

Iyer, Shrividya, B. Randazzo, Evan Tzanis, et al.. (2011). Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value in Health. 14(1). 177–183. 36 indexed citations

16.

Michna, Edward, E. Richard Blonsky, Seth L. Schulman, et al.. (2011). Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Patients With Chronic, Nonmalignant Pain: A Randomized Controlled Study. Journal of Pain. 12(5). 554–562. 118 indexed citations

17.

Michna, Edward, Seth L. Schulman, Wenjin Wang, et al.. (2011). Efficacy of Subcutaneous Methylnaltrexone in the Treatment of Opioid-Induced Constipation: A Responder Post Hoc Analysis. Pain Medicine. 12(8). 1223–1230. 14 indexed citations

18.

Randazzo, B., et al.. (2010). S1049 Characteristics of Gastrointestinal Adverse Events in Patients With Opioid-Induced Constipation and Chronic Non-Malignant Pain Treated With Subcutaneous Methylnaltrexone. Gastroenterology. 138(5). S–167.

19.

Liebowitz, Michael R., et al.. (2008). Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Current Medical Research and Opinion. 24(7). 1877–1890. 121 indexed citations

20.

DeMartinis, Nicholas, Paul Yeung, Richard Entsuah, & Amy Manley. (2007). A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Desvenlafaxine Succinate in the Treatment of Major Depressive Disorder. The Journal of Clinical Psychiatry. 68(5). 677–688. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact